Satisfaction and medication adherence in women with vulvovaginal atrophy: the CRETA

References

• Portman DJ, Gass MLS. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American menopause society. Menopause. 2014;21(10):1063–1068.
   PubMed Web of Science ®Google Scholar
• Qi W, Li H, Wang C, et al. The effect of pathophysiological changes in the vaginal milieu on the signs and symptoms of genitourinary syndrome of menopause (GSM). Menopause. 2020;28(1):102–108.
   PubMed Web of Science ®Google Scholar
• Shardell M, Gravitt PE, Burke AE, et al. Association of vaginal microbiota with signs and symptoms of the genitourinary syndrome of menopause across reproductive stages. J Gerontol A Biol Sci Med Sci. 2021;76(9):1542–1550.
   PubMed Web of Science ®Google Scholar
• Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci. 1997;314(4):228–231.
   PubMed Web of Science ®Google Scholar
• Palacios S, Nappi RE, Bruyniks N, et al. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018;21(3):286–291.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Seracchioli R, Salvatore S, et al. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study. Gynecol Endocrinol. 2019;35(5):453–459.
   PubMed Web of Science ®Google Scholar
• Palma F, Xholli A, Cagnacci A. The most bothersome symptom of vaginal atrophy: evidence from the observational AGATA study. Maturitas. 2018;108:18–23.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the revive (REal women’s views of treatment options for menopausal vaginal changes) survey. J Sex Med. 2013;10(7):1790–1799.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Carbone MM, Palma F. Prevalence and association between objective signs and subjective symptoms of vaginal atrophy: the AGATA study. Menopause. 2016;23(10):1139–1145.
   PubMed Web of Science ®Google Scholar
• Faubion SS, Kingsberg SA, Clark AL, et al. The 2020 genitourinary syndrome of menopause position statement of the North American menopause society. Menopause. 2020;27(9):976–992.
   PubMed Web of Science ®Google Scholar
• Hirschberg AL, Bitzer J, Cano A, et al. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: an EMAS clinical guide. Maturitas. 2021;148:55–61.
   PubMed Web of Science ®Google Scholar
• Alvisi S, Baldassarre M, Martelli V, et al. Effects of ospemifene on vaginal epithelium of post-menopausal women. Gynecol Endocrinol. 2017;33(12):946–950.
   PubMed Web of Science ®Google Scholar
• Alvisi S, Baldassarre M, Gava G, et al. Structure of epithelial and stromal compartments of vulvar and vaginal tissue from women with Vulvo-Vaginal atrophy taking ospemifene. J Sex Med. 2018;15(12):1776–1784.
   PubMed Web of Science ®Google Scholar
• Goldstein SW, Winter AG, Goldstein I. Improvements to the vulva, vestibule, urethral meatus, and vagina in women treated with ospemifene for moderate to severe dyspareunia: a prospective vulvoscopic pilot study. Sex Med. 2018;6(2):154–161.
   PubMed Web of Science ®Google Scholar
• Krychman M, Graham S, Bernick B, et al. The women’s empower survey: women’s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med. 2017;14(3):425–433.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Krychman M, Graham S, et al. The women’s empower survey: identifying women’s perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med. 2017;14(3):413–424.
   PubMed Web of Science ®Google Scholar
• Burkhart PV, Sabaté E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh. 2003;35(3):207–207.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Adherence to long-term therapies: evidence for action. World Health Organization. 2003. https://apps.who.int/iris/handle/10665/42682
   Google Scholar
• Gast A, Mathes T. Medication adherence influencing factors – an (updated) overview of systematic reviews. Syst Rev. 2019;8(1):1–17.
   PubMedGoogle Scholar
• Jin J, Sklar GE, Sen OV, et al. Factors affecting therapeutic compliance: a review from the patient’s perspective. Ther Clin Risk Manag. 2008;4(1):269–286.
   PubMedGoogle Scholar
• Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15.
   PubMed Web of Science ®Google Scholar
• Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521–530.
   PubMed Web of Science ®Google Scholar
• Alam MM, Sikdar P, Kumar A, et al. Assessing adherence and patient satisfaction with medication: validation of TSQM in emerging markets. Int J Pharm Healthc Mark. 2018;12(4):409–432.
   Web of Science ®Google Scholar
• Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the spanish women through and beyond menopause. Development and validation of the cervantes scale]. Med Clin. 2004;122(6):205–211.
   PubMed Web of Science ®Google Scholar
• Palacios S, Panay N, Sánchez-Borrego R, et al. Earlier treatment of vulvovaginal atrophy in post-menopausal women may improve treatment outcomes. J Gynecol Women’s Heal. 2019;16(1):555928.
   Google Scholar
• Parish SJ, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013;5(1):437–447.
   PubMedGoogle Scholar
• Simon JA, Kokot-Kierepa M, Goldstein J, et al. Vaginal health in the United States: results from the vaginal health: insights, views & attitudes survey. Menopause. 2013;20(10):1043–1048.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kingsberg S, Maamari R, et al. The closer (CLarifying vaginal atrophy’s impact on SEx and relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med. 2013;10(9):2232–2241.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Particco M, Biglia N, et al. Attitudes and perceptions towards vulvar and vaginal atrophy in Italian post-menopausal women: evidence from the European REVIVE survey. Maturitas. 2016;91:74–80.
   PubMed Web of Science ®Google Scholar
• Simon JA, Nappi RE, Kingsberg SA, et al. Clarifying vaginal atrophy’s impact on sex and relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners. Menopause. 2014;21(2):137–142.
   PubMed Web of Science ®Google Scholar
• Caruso S, Cianci S, Amore FF, et al. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. Menopause. 2016;23(1):47–54.
   PubMed Web of Science ®Google Scholar
• Palma F, Volpe A, Villa P, et al. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: the AGATA study. Maturitas. 2016;83:40–44.
   PubMed Web of Science ®Google Scholar
• Pastore LM, Carter RA, Hulka BS, et al. Self-reported urogenital symptoms in postmenopausal women: women’s health initiative. Maturitas. 2004;49(4):292–303.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Panay N, et al. Vulvar and vaginal atrophy in four european countries: evidence from the european revive survey. Climacteric. 2016;19(2):188–197.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views and attitudes (VIVA) – results from an international survey. Climacteric. 2012;15(1):36–44.
   PubMed Web of Science ®Google Scholar
• Faught BM, Soulban G, Yeaw J, et al. Ospemifene versus local estrogen: adherence and costs in postmenopausal dyspareunia. J Comp Eff Res. 2019;8(13):1111–1123.
   PubMed Web of Science ®Google Scholar
• Naidu A. Factors affecting patient satisfaction and healthcare quality. Int J Health Care Qual Assur. 2009;22(4):366–381.
   PubMedGoogle Scholar
• Barbosa CD, Balp MM, Kulich K, et al. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39–48.
   PubMed Web of Science ®Google Scholar
• Volpicelli Leonard K, Robertson C, Bhowmick A, et al. Perceived treatment satisfaction and effectiveness facilitators among patients with chronic health conditions: a Self-Reported survey. Interact J Med Res. 2020;9(1):e13029.
   PubMed Web of Science ®Google Scholar